Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats chronic severe. Sold as Avsola. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 1 application for Infliximab-axxq (sold as Avsola), first approved Dec 6, 2019, with 0 new uses approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
Stopped early: “Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in ra.”
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
RemicadeA drug with a new dosage indicated for the treatment of Crohn’s disease. · Mitsubishi Tanabe Pharma Corporation · May 18, 2017
RemicadeA drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not… · Mitsubishi Tanabe Pharma Corporation · May 13, 2016
RemicadeA drug with a new additional indication and a new dosage for the treatment of acute-phase Kawasaki's disease in patients who have not responded sufficiently… · Mitsubishi Tanabe Pharma Corporation · Dec 21, 2015
RemicadeA drug with new additional indications and a new dosage for the treatment of entero-Behcet's disease, neuro-Behcet's disease, and vasculo- Behcet's disease… · Mitsubishi Tanabe Pharma Corporation · Aug 24, 2015 · Review report
RemicadeA drug with a new dosage indicated for the treatment of Crohn's disease. · Mitsubishi Tanabe Pharma Corporation · Aug 17, 2011
RemicadeA drug with a new additional indication and a new dosage for the treatment of moderate to severe ulcerative colitis (for use only in patients who have not… · Mitsubishi Tanabe Pharma Corporation · Jun 18, 2010
RemicadeA drug with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to… · Mitsubishi Tanabe Pharma Corporation · Apr 16, 2010
RemicadeA drug with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic… · Mitsubishi Tanabe Pharma Corporation · Jan 20, 2010
Approvals in Canada (Health Canada)
First approved in Canada 222 months before the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
InflectraHospira Healthcare Corporation · Jun 4, 2014
InflectraCelltrion Healthcare Co Ltd · Jan 15, 2014
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA